Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lance Heilbrun

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Carcinogenesis|February 23, 2018
A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancerBatoul Farran, Gregory Dyson, Douglas Craig, et al.
Plos One|March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancerJulie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible PatientsUlka N Vaishampayan, Lance Heilbrun, Nitin Vaishampayan, et al.
American Journal of Translational Research|February 21, 2012
Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatmentDejuan Kong, Elisabeth Heath, Wei Chen, et al.
Plos One|March 24, 2012
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIMDejuan Kong, Elisabeth Heath, Wei Chen, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Research Communications|June 10, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate CancerElisabeth I Heath, Archana Thakur, Wei Chen, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Carcinogenesis|February 23, 2018
A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancerBatoul Farran, Gregory Dyson, Douglas Craig, et al.
Plos One|March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancerJulie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible PatientsUlka N Vaishampayan, Lance Heilbrun, Nitin Vaishampayan, et al.
American Journal of Translational Research|February 21, 2012
Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatmentDejuan Kong, Elisabeth Heath, Wei Chen, et al.
Plos One|March 24, 2012
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIMDejuan Kong, Elisabeth Heath, Wei Chen, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Research Communications|June 10, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate CancerElisabeth I Heath, Archana Thakur, Wei Chen, et al.
Pageof 2